Cargando…
CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung Cancer
Background: Although early-stage lung cancer has increased owing to the introduction of screening programs, high recurrence rate remains a critical concern. We aimed to explore biomarkers related to the prognosis of surgically resected non-small-cell lung cancer (NSCLC). Methods: In this retrospecti...
Autores principales: | Nam, Yunha, Choi, Chang-Min, Park, Young Soo, Jung, HyunA, Hwang, Hee Sang, Lee, Jae Cheol, Lee, Jung Wook, Lee, Jung Eun, Kang, Jung Hee, Jung, Byung Hun, Ji, Wonjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779436/ https://www.ncbi.nlm.nih.gov/pubmed/35054034 http://dx.doi.org/10.3390/jcm11020341 |
Ejemplares similares
-
Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer
por: Park, Song Ee, et al.
Publicado: (2022) -
Overexpression of CDCP1 is Associated with Poor Prognosis and Enhanced Immune Checkpoints Expressions in Breast Cancer
por: Zhao, Jinlu, et al.
Publicado: (2022) -
Identification of CD318 (CDCP1) as novel prognostic marker in AML
por: Heitmann, Jonas S., et al.
Publicado: (2020) -
Maximal diameter of liver abscess independently predicts prolonged hospitalization and poor prognosis in patients with pyogenic liver abscess
por: Lee, Chang Hun, et al.
Publicado: (2021) -
Predictors of Recurrence after Curative Resection in Patients with Early-Stage Non-Small Cell Lung Cancer
por: Lee, Sang Hee, et al.
Publicado: (2015)